Background: Several human studies reported that the combined use of renin-angiotensin system blockers (RASBs) and vitamin D receptor activators (VDRAs) resulted in decreased urinary protein excretion. However, it is unknown whether this combination therapy influences the incidence of cardiovascular (CV) events in dialysis patients. Methods: The study was a multicenter nonrandomized prospective cohort analysis including 1,518 patients. Patients were classified into 4 groups based on medications prescribed before dialysis initiation: those who did not receive RASBs or oral VDRAs (N group), those receiving only RASBs, those receiving only VDRAs, and those receiving a combination of RASBs and VDRAs (RD group). CV events after dialysis initiation were compared using the log-rank test. Factors contributing to the incidence of CV events were examined using multivariate Cox proportional hazard regression analysis. Results: Significant differences were observed in the incidence of CV events and 
Patient Characteristics and Data at the Time of Dialysis Initiation (Baseline)
Baseline was defined as the time at which dialysis was initiated. Body mass index (BMI) was measured at the first dialysis session. CV history was determined from medical records and defined as coronary artery disease, heart valve disease, congestive heart failure requiring hospitalization, cerebral infarction, cerebral hemorrhage, or aortic disease. Information about drug usage was obtained from the medical records. Medication use refers to the drugs taken at the time of dialysis initiation. Laboratory tests were performed using blood samples taken before the first dialysis session. Blood pressure was also measured before the first dialysis session.
Classification according to Usage of RASBs and VDRAs
Patients were classified into 4 groups: those who did not receive RASBs (angiotensin-converting enzyme inhibitors or/and ARBs) or oral VDRAs (alfacalcidol or calcitriol, 0.25-0.5 μg/day) (N group, n = 459), those treated with RASBs only (R group, n = 648), those treated with VDRAs only (D group, n = 142), and those treated with a combination of RASBs and VDRAs (RD group, n = 269).
Outcome
Study outcomes included the incidence of CV events and mortality in the 4 groups. The incidence of CV events between the start of dialysis and the end of September 2016 was compared. CV events were defined as heart failure requiring hospitalization, acute coronary syndrome, stroke, or peripheral artery disease requiring hospitalization. Heart failure was defined as hypoxemia and pulmonary congestion, pulmonary edema, or pleural effusion on chest radiograph. Acute coronary syndrome was defined as stenosis or occlusion on coronary angiography or by percutaneous coronary intervention, coronary artery bypass surgery, or electrocardiogram findings consistent with acute coronary syndrome. Stroke was defined as the presence of neurological symptoms plus brain computed tomography or magnetic resonance imaging findings indicative of hemorrhage or infarction. We defined the day of dialysis initiation as the start of the follow-up period and used "first onset of CV events," "lost to follow-up," or "no events during the follow-up period" as assessment points for CV events.
Survey of CV Events and Mortality
Answers to the prognostic survey were obtained from medical records of the AICOPP Group institutions or by sending letters to facilities where patients had been transferred for maintenance dialysis. These letters included a questionnaire regarding the category of CV events (e.g., acute coronary syndrome or ischemic stroke), date of onset, and clinical outcome.
Statistical Processing
SPSS statistics version 24 and the Easy R program were used for statistical processing [18] . Patient characteristics and baseline data were compared between the 4 groups using analysis of variance for continuous variables and the Fisher exact test for nominal variables. Incidence of CV events and mortality in the 4 groups were compared using the log-rank test for the Kaplan-Meier curves. The factors that contributed to the incidence of CV disease events were examined using univariate regression analysis. Factors that were significant in the univariate analysis (i.e., age, gender, diabetes mellitus, history of CV disease, BMI, systolic blood pressure, diastolic blood pressure, cardiothoracic ratio on chest X-ray, estimated GFR, serum creatinine, serum albumin, serum phosphorus, serum high-density lipoprotein cholesterol, serum PTH, use of calcium channel blockers, use of β-blockers, use of statins, and use of temporary catheter for vascular access) served as explanatory variables for the multivariate Cox proportional hazards analysis. The propensity score, which we calculated using logistic regression models, represented the probability that a patient would be assigned to the R group or the RD group. Using a propensity score matching procedure, the 2 groups were similarly distributed, indicating that the differences in covariates between groups were minimized. Continuous variables are expressed as means and standard deviations or medians and interquartile ranges, and categorical variables are presented as percentages. p values less than 5% were considered statistically significant. Table 1 shows patients' characteristics and baseline data in the 4 groups. Significant differences between the 4 groups were observed in age, prevalence of diabetes mellitus, BMI, diastolic blood pressure, cardiothoracic rate, hemoglobin level, blood urea nitrogen level, serum albumin level, serum uric acid level, serum potassium level, serum phosphorus level, serum cholesterol level, serum C-reactive protein level, serum 1,25-dihydroxyvitamin D level, calcium channel blocker use, β-blocker use, statin use, erythropoiesis-stimulating agent use, and use of temporary catheter for vascular access. We confirmed the duration of treatment before dialysis initiation in 359 cases for VDRAs and 710 cases for RASBs. The median (interquartile range) usage periods were 182 (55-462) and 886 (277-1,794) days, respectively. (15) 77 (17) 76 (15) 80 (14) 78 (14) Values are expressed as means (standard deviations) unless otherwise indicated. CVD, cardiovascular disease; BMI, body mass index; SBP, systolic blood pressure; DBP, diastolic blood pressure; CTR, cardiothoracic rate; eGFR, estimated glomerular filtration rate; BUN, blood urea nitrogen; LDL, low-density lipoprotein; HDL, high-density lipoprotein; CRP, C-reactive protein; PTH, parathyroid hormone; ESA, erythropoiesis-stimulating agents; VA, vascular access. Figure 1 shows the comparison of the incidence of CV disease events in the 4 groups. The median (interquartile range) of the follow-up period was 1,165 (535-1,418) days. There were 503 CV events during the follow-up period (N group, 164 events [35.7%]; R group, 214 events [33.0%]; D group, 52 events [36.6%]; RD group, 73 events [27.1%]). Significant differences were observed between the 4 groups' cumulative CV event-free rates ( p = 0.021). Table 2 shows the results of univariate analysis with the incidence of CV events as a response variable. The incidence of CV events was significantly lower in the RD group than in the N group (hazard ratio = 0.65, 95% confidence interval: 0.50-0.86, p = 0.002). In addition, the incidence of CV events was found to be associated with some factors, including age, sex, diabetes mellitus, and history of CV events. Table 3 shows the results of multivariate analyses. The incidence of CV events was significantly lower in the RD group than in the N group (hazard ratio = 0.66, 95% confidence interval: 0.47-0.93, p = 0.016). In addition, age, sex, diabetes mellitus, history of CV events, cardiothoracic rate, serum high-density lipoprotein cholesterol level, and use of calcium channel blockers were identified as independent factors affecting the incidence of CV events.
Results

Comparison of Patient Characteristics and Baseline Data
Comparison of Incidence of CV Events between the 4 Groups
Factors Affecting the Incidence of CV Events
Propensity Score-Matched Cohort
We performed logistic regression analysis using age and sex to obtain the propensity score for patients to be in the R group or the RD group. We conducted propensity score matching between the 2 groups due to the following reasons. First, we examined whether additional administration of VDRA in addition to RASB was effective. Second, it was difficult to adjust the patient profiles and baseline data among the 4 groups by logistic regression analysis. There were 247 patients in each group. Table 4 shows patient characteristics and baseline data in the 2 groups after propensity score matching. There were no significant differences in variables except for cardiothoracic rate, estimated GFR, serum uric acid, C-reactive protein, serum intact PTH, serum 1,25-dihydroxyvitamin D, use of erythropoiesisstimulating agents, and use of temporary vascular access at dialysis initiation.
Comparison of CV Events in the 2 Groups after Propensity Score Matching
There were 157 CV events during the follow-up period (R group, 88 events; RD group, 69 events). Figure 2 displays the Kaplan-Meier curves for the 2 groups after propensity score matching in terms of CV events. The incidence of CV events was significantly higher in the R CV, cardiovascular; HR, hazard ratio; CI, confidence interval; BMI, body mass index; SBP, systolic blood pressure; DBP, diastolic blood pressure; CTR, cardiothoracic rate; eGFR, estimated glomerular filtration rate; HDL, high-density lipoprotein; PTH, parathyroid hormone; VA, vascular access. Comparison of cardiovascular events between the R and RD groups after propensity score matching. Significant differences were observed between the 2 groups' cumulative event-free rates ( p = 0.032). R group, use of RASBs only; RD group, use of both RASBs and VDRAs; RASB, renin-angiotensin system blocker; VDRA, vitamin D receptor activator.
group ( p = 0.032). There were 43 CV-related deaths during the follow-up period (R group, 23 patients; RD group, 20 patients). No significant difference was observed in the 2 groups' cumulative CV-related mortality ( p = 0.570).
Discussion
The results of this study revealed an association between combination therapy with RASBs and VDRAs at the predialysis stage and a reduced incidence of CV events after dialysis was initiated. Moreover, we used propensity score matching to adjust for variables between the R and RD groups. We confirmed that there was a correlation between combination therapy and incidence of CV events after propensity score matching. Values are expressed as means (standard deviations) unless otherwise indicated. CVD, cardiovascular disease; BMI, body mass index; SBP, systolic blood pressure; DBP, diastolic blood pressure; CTR, cardiothoracic rate; eGFR, estimated glomerular filtration rate; BUN, blood urea nitrogen; LDL, low-density lipoprotein; HDL, high-density lipoprotein; CRP, C-reactive protein; PTH, parathyroid hormone; ESA, erythropoiesisstimulating agents; VA, vascular access.
We would like to highlight 2 features of this study as follows: (1) to our knowledge, this study is the first to examine the relationship between this combination therapy and the incidence of CV events among dialysis patients; (2) we set the baseline period as dialysis initiation, in contrast to many previous studies that have examined patients during predialysis or maintenance dialysis separately. The use of combination therapy before dialysis initiation might be effective in reducing the incidence of CV events in patients on dialysis by acting on the myocardium and suppressing the inflammatory cascade.
As for combination therapy with RASBs and VDRAs, there are a few basic or clinical studies that have been reported [19, 20] . Ali et al. [20] reported that the combination of angiotensin-converting enzyme inhibitors and VDRAs had a superior effect to monotherapy on reducing cardiac oxidative stress by raising antioxidant activity in diabetic rats. Concerning clinical studies, Tiryaki et al. [15] indicated that administration of VDRAs in combination with RASBs had the additional benefit of lowering albuminuria in patients with diabetic nephropathy. De Zeeuw et al. [16] conducted a multinational, placebo-controlled, doubleblind trial; this study demonstrated that the addition of 2 μg/day paricalcitol to RAS inhibition safely lowered residual albuminuria in patients with diabetic nephropathy and could be a novel approach to reducing residual renal risk in patients with diabetes. As described above, previous studies showed that RASB/VDRA combination therapy reduced urinary protein excretion; these studies did not evaluate the incidence of CV events as an outcome measure. This is the first report demonstrating the association between combination therapy with RASBs and VDRAs and the incidence of CV events. There are several possible explanations for our results: (1) VDRAs inhibit renin activity, which RASBs might increase; (2) the combination of these 2 drugs may have an additive effect on systemic inflammation; (3) combination therapy could have additive effects on the suppression of left ventricular hypertrophy via direct action on the myocardium.
The present study has the following limitations. First, this was an observational analysis, and there were some differences in the baseline characteristics and laboratory data between the 4 groups. We considered the possibility of residual confounding, although we also used the propensity score-matched cohort of the R and RD groups. Second, the duration of combination therapy before dialysis initiation was unclear. Therefore, we analyzed the duration in some patients. We considered that the patients in the R and RD groups would have received medication since the early stage of CKD because the guidelines for predialysis CKD recommend the use of RASBs. However, the appropriate timing for starting VDRAs is unclear. Hence, VDRA administration was commenced at a later stage of CKD. Third, the study did not reflect the effects of treatment after the start of dialysis. Starting dialysis would likely affect the outcomes in many ways, including blood pressure management, anemia, electrolyte balance, ultrafiltration rate, Kt/V, and hemodialysis time/session. However, we could not collect the appropriate data.
Conclusion
Combination therapy with RASBs and VDRAs in patients with CKD before dialysis initiation is associated with a reduced incidence of CV events. To the best of our knowledge, this is the first study to analyze the relationship between this treatment combination and CV outcomes. Further work is required to define this effect based on controlled studies.
